Aims

This study is aimed to explore the relationship between the single nucleotide polymorphisms (SNPs) in dopamine and serotonin metabolism genes and levodopa-induced dyskinesias (LID) development in patients with Parkinson's disease (PD).

Methods

We investigated 320 sporadic PD patients. Dyskinesia is estimated using of MDS-UPDRS scale (parts IV). PD patients were divided into PD with LID (PD-LID) and PD without LID (PD-NORM). The analysis of 18 SNPs of dopamine and serotonin receptors, catechol-O-methyltransferase, monoamine oxidase B, tryptophan and tyrosine hydroxilase, leucine-rich repeat kinase 2 was performed. The SPSS software is used for statistical analysis. Linear regression analysis and one-way ANOVA test are used.

Results

The presence of LID is evaluated in 80 PD patients, and dyskinesias are reported in 55 (68,75%) cases. Patients homozygous for the rs6275*С/С of DRD2 gene had higher values ​​of the MDS-UPDRS scale compared with heterozygous of *С/T (p=0,024; OR=1,05). It is founded that PD-LID patients have a lower frequency of the rs6280*C/C of DRD3 gene (p=0,022; OR=0,05) compared to the PD-NORM patients. Carriers of minor allele rs1491942*C of LRRK2 gene had a higher values of the MDS-UPDRS scale compared with carriers of allele *G (p=0,035; OR=3,04). Linear regression demonstrated increased LID risk for allele rs1800532*T of TPH (p=0,038; F=4,24) – this allele was associated with a higher values of the MDS-UPDRS scale.

Conclusions

Alleles rs1491942*C and rs1800532*T, and genotype rs6275*С/С could be genetic risk factors for the levodopa-induced dyskinesia development in PD patients. This pilot study continues.

The study was supported by RFBR grant No.19-015-00331